4/

of AUCATZYL® by the UK MHRA earlier this year. It has also been approved for use in eligible patients in the U.S and in the EU.

Congratulations to the whole Autolus team on this important obe-cel milestone that will change people’s lives.

Learn more here: www.uclb.com/2025/11/25/n...

3/

the specific signature of their cancer. These cells are then returned to the body as ‘living medicine’.

Crucially, obe-cel is a major improvement on existing CAR T technology, which remains active in the body over longer periods and causes fewer side effects.

The NICE decision follows approval

2/

to NHS patients ‘within weeks’. It can be used in adult patients with acute lymphoblastic leukaemia (ALL), which has not responded to treatment or has returned.

AUCATZYL® is the product name for a variant of CAR T-cell therapy which reprogrammes a patient’s T-cells to recognise and target

... model enables rapid, fair deal formation with 90%+ equity for founders of non-patentable intellectual property (IP).

Remind yourself of USIT and how it benefits research commercialisation 👉 www.uclb.com/2024/05/20/u...

... to the expert workshop on this guidance last week, discussing how to attract investment while protecting institutional interests and be financially sustainable.

She shared more about the UK’s experience through the USIT Guide, our founder-friendly equity deals: our Portico Ventures

2/

... even AZ and Merck have chosen to retreat.

The cutting-edge tech & life-changing research coming out of institutions like UCL could help realise the first homegrown trillion-pound company.

There is plenty to be excited about - read the article here (p39): onenucleus.com/publications

2/

Previously, he was focused on producing excellent academic research, but now - after licensing his own work - Stefan is keen to patent technologies and see them used in real-world applications, alongside writing high quality, impactful papers.

See you at our next IO Converse in January?

2/

... one that is already offering hope to blood cancer patients.

Emily Henders, a 37-year-old biology teacher & mum of two, shared her decision to participate with Sky News.

We look forward to seeing how this trial develops! 👏

Read more: www.uclb.com/2025/10/24/a...

3/

This ‘one-time’ treatment sees patients receive an infusion of their own T-cells, modified to recognise and hunt down rogue elements in their immune system, which are the underlying cause of multiple sclerosis.

The beginning of the trial marks a significant expansion of the therapy platform...

2/

The report also noted that UCL has 'a proportionally high number of spinouts' in the government's priority sectors.

Read more about these stats: www.uclb.com/2025/10/21/u...

Ana said:
> 𝗘𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲: evaluating ideas, shaping business plans, offering IP or licensing advice
> 𝗡𝗲𝘁𝘄𝗼𝗿𝗸𝘀: connecting founders with advisers & collaborators
> 𝗙𝗶𝗻𝗮𝗻𝗰𝗲: helping with grant applications, translational funding, providing PoC funds to test / prototype ideas

and more were vital.

UCLB is proud to call the Euston Knowledge Quarter home and be leading the momentum with:

- 95 active spinouts across healthcare, AI, and tech
- Over £3 billion raised in external investment over the last five years
- and the creation of 2,400 jobs.

The trajectory of this possibility is incredibly exciting:
adding £3.5 billion to the economy, creating 30,000 new jobs, and driving breakthroughs in cancer, Alzheimer’s, sustainable energy & more.

Such growth would exceed that of Boston's Kendall Sqaure...!

... in introducing an innovative protein pore into ONT's devices.

Dr Barny Cox, Senior Business Manager at UCLB, will chair the session on:

📅 16 October 2025
🕑 12.30pm-2pm (light lunch provided)
📍 90 Tottenham Court Road

Register your place here: www.eventbrite.co.uk/e/io-convers...

2/

... of development of many of our highly successful spinouts across a multitude of disciplines.

Take a look at our stats on PoC funding or find out more about how it's helped UCL spinouts: www.uclb.com/2025/09/23/t...

3/3

Both were nominated by UCLB.

PoC funding has been a vital part of the commercialisation landscape at UCL for almost 20 years.

It helps bridge the funding gap between research grants and investment, supporting the early stages...

2/3